Is EINECS 249-451-7 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EINECS 249-451-7? Is EINECS 249-451-7 safe for nursing mother and child? Does EINECS 249-451-7 extracts into breast milk? Does EINECS 249-451-7 has any long term or short term side effects on infants? Can EINECS 249-451-7 influence milk supply or can EINECS 249-451-7 decrease milk supply in lactating mothers?

• DrLact safety Score for EINECS 249-451-7 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of EINECS 249-451-7 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that EINECS 249-451-7 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using EINECS 249-451-7 .
• It is recommended to evaluate the advantage of not breastfeeding while using EINECS 249-451-7 Vs not using EINECS 249-451-7 And continue breastfeeding.
• While using EINECS 249-451-7 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

One case of cyanosis (blue skin discoloration), bradicardia, hypotermia and hypotension in a 5-days old girl whose mother was on 50 mg every 12 hours was reported. It does concentrate in breast milk. Several reports have shown excessive excretion to mother's milk.

Because of EINECS 249-451-7's relatively extensive excretion into breastmilk and its extensive renal excretion, other agents may be preferred while nursing a newborn or preterm infant or with high maternal dosages.[1][2] Infants older than 3 months of age appear to be at little risk of adverse effects from EINECS 249-451-7 in breastmilk. Timing breastfeeding with respect to the time of the EINECS 249-451-7 dose appears to be of little benefit in reducing infant EINECS 249-451-7 exposure because the time of the peak is unpredictable.[3]

A study of mothers taking beta-blockers during nursing found a numerically, but not statistically significant increased number of adverse reactions in those taking any beta-blocker. Although the ages of infants were matched to control infants, the ages of the affected infants were not stated. Of 13 mothers taking EINECS 249-451-7, one reported lethargy in her breastfed infant; she was also taking other unspecified drugs for hypertension.[17] Cyanosis, bradycardia and hypothermia occurred in a 5-day-old infant probably because of EINECS 249-451-7 in breastmilk. Her mother was taking EINECS 249-451-7 50 mg twice daily. Symptoms continued until day 8 when breastfeeding was discontinued.[9] No difference between resting and crying heart rates were observed in 22 breastfed (extent not stated) infants aged 3 to 4 months whose mothers were taking EINECS 249-451-7 in an average oral dosage of 49 mg daily. This finding indicated that the infants were experiencing no beta-adrenergic blockade from EINECS 249-451-7 in breastmilk.[3] Other authors have reported 15 infants aged 3 days to 2 weeks exposed to EINECS 249-451-7 in breastmilk with no signs of adverse effects. Maternal dosages were 50 or 100 mg daily.[5][6][7][13][15][16][18]

One unusual case of oligomenorrhea, hyperprolactinemia and galactorrhea was reported in a 38-year-old woman who had been taking EINECS 249-451-7 for about 18 months. Prolactin values returned to normal within 3 days of discontinuation of EINECS 249-451-7. Galactorrhea slowly lessened and disappeared one month after EINECS 249-451-7 discontinuation.[19]